Emerging Therapeutic Areas in GCC

Strategic national frameworks across Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE drive the pharmaceutical sector toward transformative therapies.

DATE
October 27, 2025
CATEGORY
Blog

What’s Next for Pharma?

Strategic national frameworks across Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE drive the pharmaceutical sector toward transformative therapies. These initiatives integrate advanced research with regional health priorities, fostering collaborations that enhance access to innovative treatments. Government-led programs, supported by partnerships with global pharmaceutical entities, establish the region as a center for medical progress. This focus addresses prevalent conditions through targeted innovations, emphasizing sustainability and efficiency in healthcare delivery.

Current Landscape of GCC Pharmaceutical Development

Health strategies in the GCC prioritize integration, operational efficiency, and patient-centered innovation. The UAE Health Council refines its strategic approaches, enhancing sector coordination and launching projects that strengthen competitiveness.

Chronic diseases remain a dominant concern, accounting for 77% of deaths in the UAE, while mental health and rare disorders are increasingly prioritized. Saudi Arabia utilizes digital tools, such as the Sehhaty app, to incorporate public input and support Vision 2030 goals, including the expansion of specialized centers and preventive programs. Qatar’s cancer plan outlines timelines for targeted programs, while Oman’s focus on industry localization enhances supply chain resilience. Kuwait’s pharmaceutical market is poised for growth through expanded local manufacturing.

Investment Trends and Joint Initiatives

Rising expenditures on non-communicable diseases, genomic research, and digital health shape regional investments. The UAE has sequenced over 600,000 genomes through the Emirati Genome Programme and utilizes AI platforms like EJADA to reduce chronic disease treatment costs by 30%. Meanwhile, Saudi Arabia and Qatar are channeling funding into biotech and health tech startups. Joint initiatives, such as Mu’azzaz, promote healthier public environments, and mental health campaigns provide community support and early detection services. Startups and institutions complement these efforts with digital platforms, chronic care management, and lifestyle programs.

Regulatory Support and Harmonization

Regulatory bodies across the GCC, including the UAE’s Ministry of Health and Prevention and Saudi Arabia’s SFDA, streamline product registrations, certifications, and approvals for advanced therapies. Harmonized standards, GCC-wide GMP certifications, and expedited review processes facilitate cross-border innovation, adoption of AI-integrated solutions, and alignment of resources. These efforts foster a seamless ecosystem where emerging therapies, technology, and patient-centric care converge, ensuring the region remains at the forefront of pharmaceutical development.

Gene Therapy: Pioneering Genetic Interventions

Gene and stem cell therapies are at the forefront of GCC regenerative medicine, targeting genetic disorders through precise edits and tissue repair. These approaches align with national strategies to tackle hereditary conditions like thalassemia and sickle cell anemia, prevalent due to regional consanguinity rates over 60% in places like Saudi Arabia.

UAE Advancements in Gene Therapy

The Department of Health – Abu Dhabi (DoH) introduced CRISPR/Cas9-based treatments for sickle cell disease and thalassemia, with the first patient procedure scheduled for April 2025 at Yas Clinic Hospital. DoH, in collaboration with UCSF and IGIE, established the world’s first genome surgery centers on July 4, 2025, focusing on modifying or replacing faulty genes to treat diseases.

Additionally, DoH partnered with CNH in July 2025 to advance pediatric cell and gene therapies, improving access for children in the UAE. An agreement dated April 16, 2025, with MIPT emphasizes gene therapy innovation through clinical trials and non-invasive prenatal testing.

DoH and GEMMABio Therapeutics, along with M42 and PureHealth, plan to develop gene therapies for spinal muscular atrophy type 1 in children.

Cell and Advanced Therapy Medicinal Products

Complementing gene therapy, cell-based approaches form part of advanced therapeutic strategies. The UAE’s standards for pan-human biobanks define Advanced Therapy Medicinal Products for gene therapy, cell therapy, and tissue engineering. These products treat, prevent, or diagnose diseases through innovative methods. DoH’s paediatric collaborations emphasize cell therapies for young patients. Such developments integrate with broader genomic efforts.

Stem Cell Therapy: Regenerative Horizons

Stem cell therapy complements gene interventions by utilizing cells such as embryonic stem cells (ESCs), adult stem cells, and induced pluripotent stem cells (iPSCs) to repair damaged tissues in conditions including diabetes, cardiovascular diseases, and neurological disorders. In the UAE, Dubai hosts the region’s first Stem Cell Bank, positioning the country as a hub for research and potential stem cell tourism, supported by events like the MENA Stem Cells Forum.

The DoH’s 2019 standards regulate stem cell therapies and regenerative medicine, ensuring ethical practices aligned with international norms, including the collection of stem cells from adults, placentas, or leftover IVF embryos with informed consent. Mesenchymal stem cells have shown promise in treating COVID-19 complications, driving further trials.

Saudi Arabia’s Contributions

Saudi Arabia’s Food and Drug Authority (SFDA) joined global efforts to harmonize standards for gene therapy products, as announced in a July 2025 newsletter. The SFDA participates in international trials for gene therapy in haemophilia B, integrating the Kingdom into global research networks.

The Public Investment Fund backs local manufacturing of cell and gene therapies, with plans for dedicated facilities. The King Abdullah International Medical Research Center (KAIMRC) leads translational stem cell work for hematological diseases, guided by a 2003 fatwa permitting cells from consented adults, children, or miscarried embryos while banning willful abortions or therapeutic cloning.

Regional Regulatory Framework

Clinical trial regulations in the GCC specify 60 working days for approvals of gene therapy studies. Guidelines for accreditation ensure compliance in bioequivalence and gene-related trials. UAE’s MoHAP and Dubai Health Authority enforce standards for autologous stem cells, while Qatar’s Biomedical Research Institute (QBRI) advances stem cell trials for cancer and diabetes under ethical oversight.

Challenges include harmonizing frameworks, Saudi Arabia’s SFDA contrasts with UAE’s local guidelines, and building public awareness, where surveys show over 50% of Saudis express safety concerns despite 90% interest in learning more.

  • Innovative Explorations: Saudi Arabia’s Biogravity Initiative examines space-based research for advanced medical solutions.
  • Broader Applications: Qatar aims to establish a CAR-T and gene therapy center by 2026.

Bahrain’s genomic conferences, such as BIPHC 2025, highlight regional commitments. These efforts, alongside institutions like Egypt’s National Research Centre for liver therapies, reduce long-term disease burdens through targeted interventions.

Precision Medicine: Tailoring Treatments to Individual Profiles

Precision medicine in the GCC utilizes genomics and analytics to customize therapies, enhancing efficacy and reducing adverse effects.

Genomic Initiatives Across the GCC

The UAE’s Emirates Genome Council has gathered data from over 600,000 citizens, mapping genetic and hereditary diseases for personalized care. DoH’s genomic medicine initiative uses individual genomic information to understand the genetic bases and improve diagnostics.

DoH collaborated with Illumina in June 2024 to expand research in genomics and precision medicine across disease areas. A 2023 partnership with AbbVie advances personalized medicine and genomics.

Collaborative Partnerships and Programs

Partnerships between GCC governments and global pharmaceutical companies accelerate precision medicine implementation through shared expertise and resources.

In the UAE, DoH signed a Memorandum of Understanding (MoU) with Illumina in 2024 to expand genomics research across disease areas, providing access to advanced sequencing technologies. A 2023 MoU with AbbVie and M42 advances personalized medicine in immunology and oncology, focusing on genomic integration for diagnostics. In April 2025, DoH partnered with PureHealth, M42, Illumina, NYU Abu Dhabi, Khalifa University, and the Institute for Healthier Living Abu Dhabi to establish frameworks for precision therapies.

MSD GCC collaborates with DoH on digital technologies for precision immunology, including AI-driven approaches to tailor treatments. This includes real-world evidence studies for oncology, initiated in 2023.

Bahrain’s program involves international research institutions for data analysis, while Saudi Arabia’s SHGP partners with global sequencing leaders. Qatar’s genomic guidelines encourage collaborations with academic centers like Sidra Medicine.

Program Highlights:

  • UAE’s Personalised Precision Medicine Programme for Oncology, launched by DoH, targets breast cancer with genetic testing for 1,030 annual cases.
  • GCC-wide: Harmonized ethical frameworks for genomic research under MoPH Qatar.

These alliances facilitate data sharing and technology transfer, thereby accelerating the clinical adoption of new technologies.

Applications in Cardiovascular Disease

Precision medicine applies genomic insights to cardiovascular disease (CVD), a leading cause of mortality in the GCC, by identifying genetic risk factors and tailoring interventions.

AstraZeneca’s Cardiovascular, Renal and Metabolism (CVRM) portfolio integrates precision approaches to address interconnected CVRM conditions, estimating that one in three patients has multiple comorbidities. In the UAE and Saudi Arabia, this includes genetic testing for dyslipidaemia, where high LDL-C contributes to 2.6 million global deaths annually, to optimize statin therapies.

DoH UAE supports early access to targeted therapies like WINREVAIR for pulmonary arterial hypertension, reducing clinical worsening by 84% in trials, addressing vascular narrowing in CVD patients. Saudi Arabia’s Health Sector Transformation Strategy incorporates genomic screening for CVD risk under Vision 2030, focusing on hypertension and heart failure.

  • Regional Focus:
    • GCC Ministers of Health initiative on CVD, emphasizing genetic profiling for prevention.
    • AstraZeneca GCC: Precision biomarkers for atrial fibrillation, affecting stroke risk in 2-4% of anticoagulant users annually.

These applications enable proactive management, reducing CVD burden through personalized risk assessment.

Oncology: Enhancing Detection and Targeted Therapies

GCC oncology advancements feature innovative diagnostics and treatments, aligned with national plans to lower cancer mortality.

Dubai Health Authority introduced advanced cancer treatment technologies in 2025. MoHAP’s partnership with AstraZeneca aims to facilitate early detection of lung cancer.

Qatar’s plan includes clinical peer review groups by Q4 2025 for urgent referrals. Saudi Arabia’s King Saud University Medical City patented a device for oral cancer radiation side effects.

DoH and MSD advance oncology research in Abu Dhabi. AstraZeneca’s GCC hub enhances oncology delivery.

  • Screening Programs: Bahrain supports GCC efforts against non-communicable diseases.
  • Hub Development: Abu Dhabi Emerges as a Life Sciences Hub for Oncology.

These initiatives aim to boost survival rates via early interventions. Roche’s expansion into new therapy segments includes diagnostics for disease areas.

Mental Health in the GCC: From Stigma to Strategy

Mental health in the GCC has shifted from being a sidelined issue to becoming a strategic pillar of healthcare. With urbanization and post-pandemic stressors increasing pressure on communities, governments now recognize psychological well-being as essential. A 2020 study revealed that more than half of UAE residents had experienced at least one mental disorder, underscoring the urgency for stronger frameworks across Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE.

Building Supportive Frameworks

Several initiatives highlight this regional momentum. The UAE’s AED 105 million Mental Wealth Framework, launched in July 2024, is a five-year plan designed to promote early detection and support vulnerable groups, including children and the elderly. Saudi Arabia, under Vision 2030, has expanded its mental health clinics by 20% since 2021, thereby strengthening access to outpatient services at leading institutions, such as Al Amal Hospital. Alongside these efforts, community campaigns and awareness programs, such as Mental Health AE’s events and workshops, are reducing stigma and encouraging dialogue.

Expanding Access and Awareness

Access to care is also improving, with free services available to nationals, expanding insurance packages for expatriates, and private providers offering therapy and youth-focused programs. Telehealth has played a significant role in expanding its reach, particularly among younger populations. At the regulatory level, the UAE’s Federal Law No. 10/2023 ensures job protection, privacy, and patient rights, reinforcing trust in the system. Public awareness campaigns have engaged hundreds of thousands across the GCC, marking a cultural shift toward openness and acceptance. Together, these measures are building resilience and turning mental health into a regional strength.

Digital Health and AI: Integrating Technology for Efficient Care

In the GCC, digital health and AI are core drivers of healthcare evolution, powering tools that provide predictive insights, streamline operations, and expand access. These advancements align with national visions, refining resource use and decision-making while fueling economic contributions through tech integration.

AI Policies and Summits

GCC nations have implemented detailed AI policies to guide the development of ethical healthcare applications, emphasizing oversight, innovation, and collaboration across borders.

Bahrain’s Information & eGovernment Authority introduced the National Policy for the Use of Artificial Intelligence in 2025, incorporating the GCC Ethics Manual for sectors like health. It prioritizes secure data handling and broad inclusion in AI rollout.

The UAE’s Charter for the Development and Use of Artificial Intelligence outlines rules for fair access and adherence to law, aligning with the broader UAE AI Strategy. The Cabinet endorsed an international AI position in 2025 to tackle worldwide issues.

Oman’s National AI Policy 2025 outlines guidelines for secure AI in healthcare and resources, supporting Oman Vision 2040. Saudi Arabia’s Artificial Intelligence Regulation platform emphasizes ethics, forecasting AI’s role in a $ 58.8 trillion global economy by 2030.

Notable 2025 summits included Saudi Arabia’s Global AI Summit in Riyadh, which delved into the applications of healthcare AI. The UAE’s World Government Summit featured discussions on AI governance, while Oman’s COMEX 2025 showcased digital health and AI applications. Kuwait’s Central Banks in the Age of Artificial Intelligence Conference explored health resource implications.

  • Policy Impacts:
    • UAE: Abu Dhabi Government Digital Strategy 2025-2027 commits AED 13 billion to pioneer a fully AI-native government.
    • GCC: All members adopt the harmonized ethics manual for shared AI health uses.

Such frameworks and gatherings bolster patient protection and operational gains.

Applications in Diagnostics and Resource Management

AI is reshaping diagnostics and resource handling in GCC healthcare, boosting precision and cutting inefficiencies.

For diagnostics, Roche expanded its digital pathology platform in 2025, incorporating over 20 AI algorithms for cancer detection and expedited tissue reviews. This aids regional oncology, shortening diagnostic periods by up to 30% at linked sites.

AstraZeneca’s MILTON AI, debuted in 2024 and rolled out GCC-wide in 2025, forecasts over 1,000 illnesses pre-symptoms via UK Biobank info, supporting early steps in UAE and Saudi settings. Oman’s Ministry of Health released AI radiology guidelines in August 2025, requiring ongoing performance checks.

In resource management, Oman’s AI Strategy 2025 leverages AI to improve healthcare distribution, mitigate cybersecurity threats, and optimize supply chain efficiency. Saudi Arabia’s Digital Government Authority employs generative AI for anticipatory health shifts.

The UAE’s DoH partnered with Microsoft in 2025 to leverage AI in diagnostics and population oversight, enhancing facility analytics.

  • Key Metrics:
    • Roche: AI spots oncology biomarkers 25% sooner.
    • AstraZeneca: AI in markets like GCC lowers costs by focusing on high-risk referrals.

Overall, these uses reduce losses and elevate service quality.

AI Applications in Mental Health

AI supports GCC mental health efforts by aiding detection and customization, meeting growing needs in the region.

The UAE’s DoH signed a 2025 MoU with Viatris for an AI training platform to support primary doctors in identifying disorders early through expert input. It addresses issues impacting 20% of UAE adults, using AI for sorting and handling.

Novartis utilizes AI to accelerate neuroscience research, processing data for personalized therapies in the GCC region. Saudi Arabia’s HUMAIN, PIF-launched in 2025, funds AI for health, covering mental predictive models.

Oman’s AI Policy 2025 focuses on mental health apps to improve life quality through various projects. Bahrain’s policy extends to healthcare, backing AI bots for initial checks.

  • Regional Advances:
    • UAE: Platform trains 1,000 doctors yearly, cutting delays by 40%.
    • GCC: Ethics rules safeguard privacy in mental AI data.

This approach eases stigma and gaps, encouraging forward-thinking support.

Regional Events and Hackathons

The 2025 events and hackathons drive AI healthcare progress in the GCC, fostering teamwork and delivering real-world solutions.

Saudi Arabia’s Innovation Path Hackathon 2025, organized by the Digital Government Authority and the Ministry of National Guard Health Affairs, focuses on AI-driven health solutions. The Global Occupational Safety and Health Hackathon eyes AI for work wellness.

The UAE’s EHS held its second Innovation Hackathon in September 2025, with over 200 participants tackling health-related puzzles. Abu Dhabi Global Health Week’s Smart Health Hackathon prized ideas like CloudCare for elder care.

Oman’s COMEX 2025 featured AI health demo zones, with Qatar’s MoPH supporting similar events as part of its strategy. UAE’s TDRA Hackathon 2025 features health tracks.

  • Event Outcomes:
    • ADGHW Hackathon: $200,000 prizes for 2025 digital health winners.
    • Saudi Hackathon: Aims for 500+ AI health entries.

These venues speed uptake and skill building across Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE.

Contributions from Global Pharmaceutical Companies

Global pharma companies are active partners in the GCC, bringing their resources to local projects and helping speed up access to new treatments.

Focus Areas of Leading Firms

These firms align their work with GCC health needs, such as cancer care, immune disorders, and heart conditions.

AstraZeneca in the Gulf works on oncology, respiratory issues, and rare diseases, including the Lung Ambition Alliance to double lung cancer survival by 2025. GSK covers HIV, respiratory, immunology, and oncology, with specialty drugs for key markets.

Roche focuses on diagnostics and oncology, with plans to expand into areas such as oral antidiabetics and STI tests in 2025. Pfizer allocates 40% of its R&D efforts to oncology, with over 50 programs, including antibody-drug conjugates for urothelial cancer.

Novartis targets neuroscience, cardiovascular, and immunology, serving 296 million patients globally. AbbVie handles immunology, oncology, neuroscience, and eye care for chronic issues.

  • GCC Matches:
    • AstraZeneca: CVRM tools for comorbidities in about one-third of patients.
    • GSK: Vaccines and meds for high-risk infections.

This alignment helps tackle our most significant health challenges directly.

Sustainability and Therapy Pipelines

Companies are linking green practices with new drug development, aiming for both patient benefits and environmental responsibility.

AstraZeneca’s Ambition Zero Carbon includes transitioning inhaler propellants to a near-zero global warming potential option, with the first next-generation inhaler expected to launch in 2025 and a goal to become carbon negative across its value chain by 2030. Its pipeline includes a broad range of oncology programs with multiple Phase 3 studies anticipated in 2025.

GSK, through ViiV Healthcare, presented data at CROI 2025 showing zero HIV acquisition with Apretude (cabotegravir long-acting) for PrEP in implementation studies. The company participates in global sustainability initiatives aligned with net-zero health goals.

Roche is advancing AI-powered diagnostic tools in oncology, integrating multiple AI algorithms to enhance cancer diagnosis workflows.

Pfizer’s vepdegestrant demonstrated significant Phase 3 efficacy in ESR1-mutant ER-positive, HER2-negative breast cancer.

Novartis maintains a robust development pipeline across multiple therapeutic areas, supporting a strong outlook for future growth.  AbbVie’s 20+ programs include ABBV-706 for lung cancer in 2025.

  • Pipeline Updates:
    • AstraZeneca: Phase I/II trial of AZD0305 in relapsed/refractory multiple myeloma is ongoing in 2025, following initiation in late 2023.
    • GSK: 43 respiratory abstracts at ATS 2025.

Such work supports GCC goals for sustainable healthcare.

Regional Offices and Partnerships

Local offices and ties help these companies connect directly with GCC systems, from training to joint projects.

AstraZeneca’s Dubai headquarters manages teams in Abu Dhabi, Kuwait, Bahrain, Qatar, and Oman, working with MoHAP on lung screening initiatives and the SFDA on regulatory matters. GSK’s Jeddah office manages HIV and vaccines through the GSK-Pfizer ViiV partnership.

Roche links with the Dubai Health Authority for diagnostics. Pfizer shares oncology data from ASCO GU 2025 with local centers. Novartis and AbbVie base in the UAE, with AbbVie’s DoH deals for immunology.

  • Partnership Examples:
    • AstraZeneca: Net-zero efforts with GSK, Roche, and Novartis.
    • GSK-Pfizer: ViiV for HIV in the region.

These connections make global expertise work for us right here.

Conclusion: Forging a Legacy of Therapeutic Excellence

The GCC’s pharmaceutical landscape stands at a pivotal juncture, where milestones in gene therapy, integrations of precision medicine, breakthroughs in oncology, and innovations in digital health converge to redefine patient outcomes. From the UAE’s pioneering genome surgery centers to Saudi Arabia’s harmonized regulatory standards and Qatar’s targeted therapy timelines, these developments underscore a unified commitment to evidence-based progress. Supported by robust local manufacturing and strategic pharmaceutical partnerships, the region is not merely adapting to global trends but actively shaping them, with projections indicating sustained growth in therapeutic accessibility by 2030.

As Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE navigate these horizons, the emphasis on collaborative frameworks, evident in initiatives like the GCC Pharmaceutical Congress and joint AI ethics guidelines, ensures equitable benefits across the MENA region. Policymakers, researchers, and industry leaders are positioned to amplify these gains through continued investment in clinical trials and data infrastructure. By prioritizing these emerging areas, the GCC can cultivate a resilient healthcare ecosystem that extends healthier lifespans and economic vitality, inviting all stakeholders to contribute to this enduring legacy of innovation.